fig5

Figure 5. DIFLD and Hepatic Failure reports linear regression analysis by common drug. (A) Year-over-year changes in DIFLD cases reported to the FAERS by common drugs from 2004 to 2023; (B) Year-over-year changes in hepatic failure cases reported to the FAERS by common drugs from 2004 to 2023; (C) The table summarizes the trends in hepatic failure and DIFLD cases reported to the FAERS from 2004 to 2023 for various drugs. It presents the cases change per year and the statistical significance (P-values) for both hepatic failure and steatosis. We confirm that the figure is original and does not require external copyright permission. DIFLD: Drug-induced fatty liver disease; FAERS: Food and Drug Administration’s Adverse Event Reporting System; FDA: U.S. Food and Drug Administration; CI: confidence interval; NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs.